Publication date: Aug 30, 2023
This study sought to examine prostate-specific antigen testing rates before, early in, and later in the COVID-19 Pandemic. Our cohort included test results from men >45 years who received prostate-specific antigen testing at least once at our institution from November 2018-September 2021 and were alive at the end of that period. Monthly trends were evaluated for three periods: Pre-COVID (November 2018-February 2020), early-COVID (March-May 2020), and late-COVID (June 2020-September 2021). Univariable and multivariable analysis tested the impact of these periods on prostate-specific antigen testing rate, after accounting for available confounders. All analyses were stratified by prostate cancer diagnosis status. A total of 141,777 prostate-specific antigen tests met inclusion criteria. The monthly number of tests in men without prostate cancer declined from 3,669 pre-COVID to 1,760 early-COVID (52% decrease; P=0. 0086) before increasing to 4,171 (14% increase from pre-COVID; P
| Concepts | Keywords |
|---|---|
| Accounting | COVID-19 |
| June | Delayed Diagnosis |
| Pandemic | Health Services Accessibility |
| Prostate | Prostate-Specific Antigen |
| Prostatic Neoplasms |
Semantics
| Type | Source | Name |
|---|---|---|
| disease | MESH | prostate cancer |
| pathway | KEGG | Prostate cancer |
| disease | MESH | COVID-19 Pandemic |
| disease | VO | monthly |
| drug | DRUGBANK | Methionine |